Lanvis

Tioguanine, the active ingredient in Lanvis, is a thiopurine presented as an oral formulation for oral use. It is employed in the treatment of certain leukemias, specifically acute lymphoblastic leukemia and chronic myeloid leukemia, and works by interfering with DNA synthesis in malignant cells. The drug is indicated for use under specialist supervision in adult and pediatric oncology patients.

GNH USA supplies Lanvis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies, clinics and procurement teams worldwide.

Lanvis, a thiopurine antineoplastic, is used in the management of malignant blood disorders.

Acute lymphoblastic leukemia: contributes to remission induction in patients. Chronic myeloid leukemia: assists in disease control and cytogenetic response. Maintenance therapy in leukemia: helps sustain remission after initial treatment.

Tioguanine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea or vomiting. - Diarrhea or abdominal discomfort. - Loss of appetite. - Mild leukopenia or neutropenia. - Rash or mild skin irritation. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe myelosuppression leading to infection risk. - Hepatotoxicity with jaundice. - Acute pancreatitis. - Life‑threatening infections. - Hypersensitivity reactions including fever and eosinophilia. - Secondary malignancies such as lymphomas.

Tioguanine therapy requires careful monitoring and patient counseling.

Monitor blood counts: perform regular CBC to detect myelosuppression. Assess liver function: check hepatic enzymes before and during therapy. Screen for infections: avoid use in active infections. Avoid in patients with known hypersensitivity to thiopurines. Pregnancy and lactation: use only if benefits outweigh risks and after specialist consultation. Store at ambient temperature: keep in original container, protect from moisture and light.

Tioguanine can interact with several medicines, altering its safety profile.

Major Interactions (Avoid): - Allopurinol: may increase tioguanine toxicity – avoid co‑administration. - Azathioprine: additive myelosuppression – avoid concurrent use.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect – monitor INR. - Methotrexate: increased risk of bone marrow suppression – monitor blood counts. - Corticosteroids: may alter tioguanine metabolism – adjust dose as needed.